This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Evidence-Guided Molecular Profiling Offers New Hope For Oncologists Managing Difficult-to-Treat Cancers

AMSTERDAM, Sept. 29, 2013 /PRNewswire/ -- Caris Life Sciences announced today data from two studies presented at the 2013 European Cancer Congress (ECC 2013), which demonstrate the potential of evidence-guided molecular profiling to immediately improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) origins as well as rare tumors and cancers that have been refractory to treatment.

Molecular Profiling in Carcinoma of Unknown Primary (CUP)

Results from the study, 'Biotheranostic profiling of CUP: paradigm shift in the management of CUP', show that molecular profiling may positively influence patient outcomes when the primary site of the patient's tumor is unknown by providing oncologists with critical new information to help them select optimal treatment. 1

Using a variety of profiling technologies to assess the biomarkers associated with the potential for drug response, the researchers were able to find targets for which there are existing cancer drugs in 77% of the tumors profiled. 1

Zoran Gatalica, MD, DSc, Medical Director, Caris Life Sciences and an Adjunct Professor of Pathology, Creighton University School of Medicine, reported that his team's research has shown that investigating the biology of a CUP patient's tumor is a potentially effective way of developing an actionable treatment plan for most patients. 

"Previous attempts to characterize cancer of unknown primary (CUP) have only managed to provide a statistical likelihood of a potential primary organ site, and for the most part have not addressed the question of which treatments are likely to be effective," said Dr. Gatalica. "We set out to do just that in a large group of over 1,350 CUP patients. This is the largest group to date to have their tumor biomarker profiles characterized." 

"We believe that our research, based on the Caris Molecular Intelligenceā„¢ service, signals a paradigm shift in the treatment of CUP," added Dr. Gatalica. "With this strategy, physicians can build a treatment plan based on changes in cancer cells which are known to be associated with the potential for benefit from specific drugs. We could be looking at the evolution of a new standard of care for these patients who badly need new options."

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs